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ABSTRACT 
 
Epigenetic is defined as heritable modification or properties of the functional genome 
that are not directly embedded in the DNA sequence. Epigenetic changes include DNA 
methylation, histone modifications and RNA-mediated gene silencing. Genomic 
imprinting is a mechanism of allele-specific epigenetic control of gene expression 
according to parent of origin. Alteration of genomic imprinting is associated with 
tumorigenesis. This thesis is aimed to study epigenetic aspects of human cancer like 
adrenocortical carcinoma, human cancer cell line, Hep3B and JEG-3 and neural 
progenitor cells. 
In study I we have investigated the effect of histone deacetylase inhibitor (HDACi), 4-
PB on the gap junctional communication between neuronal progenitor cells (NPC) and 
glioblastoma multiforme (GBM) cells involving connexin 43 (Cx43). 4-PB increased 
Cx43 in-vitro, and NPCs may be used as a delivery vehicle for enzyme prodrug therapy 
for GBM. 
The purpose of study II was to explore the regulation of neural stem cell differentiation 
by 4-PB involving de novo DNA methyltransferase DNMT3B. For this study we used 
human embryonic stem cells, NGC-407. Treatment of the human embryonic stem cells, 
NGC-407 with 4-PB, suppressed astrocytic and neuronal differentiation along with 
DNMT3B immunoreactivity. This suggests that 4-PB preserve the immature phenotype 
of NGC-407 by involving epigenetic mechanism of de novo methylation. 
In study III we examined the role of transcription factor PLAG1 on IGF2 P3 promoter 
regulation in human cancer cell lines Hep3B and JEG-3. We also studied the ability of 
PLAG1 to override the insulator effect of the H19 Imprinting Control Region (ICR) in 
a GFP reporter construct. We conclude that PLAG1 binding to the IGF2 P3 promoter is 
cell line specific and PLAG1 acts as a transcriptional facilitator to partially override the 
insulation at H19 ICR. 
In study IV we identified associations of proteomic profiles with aberration of 
H19/IGF2 locus in adrenocortical malignancy. Proteomic profiles were acquired from 
ACAs and ACCs. We revealed that IGF2, along with miR-483-3P and miR-483-5P 
overexpression in ACCs, is associated with tumor-type specific proteome profiles.  We 
have shown a positive correlation between IGF2 and its miR-483-3P and miR-483-5P 
along with H19 and its miR-675. We suggest that specific proteomes associated with 
microRNAs in the H19/IGF2 locus in ACCs may be used as therapeutic markers and 
patient follow-up. 
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1. INTRODUCTION 
 
 
 
1.1   EPIGENETICS 
 
1.1.1 Epigenetic principles 
 
Epigenetics refers to modification or properties of the functional genome that are not 
directly involved in the DNA sequence but heritable through cell division
1-3
. Or, 
simply, “epigenetics” is the alterations that are conveyed over several rounds of cell 
divisions, but that do not change the nucleotide sequence of DNA. In 1942 the term” 
epigenetic” was first invented by Conrad Waddington to refer to “the interactions of 
genes with their environment that bring the phenotype into being” 4. The significance of 
epigenetic principles is focused by the fact that in every given organism all cells share 
an identical genome, but they exhibit different functional and morphological properties. 
The biological events that are not directly programmed in the DNA sequence have been 
reflected as epigenetic phenomena which include genomic imprinting, differentiation 
and X-chromosome inactivation. Not only normal biological occurrences, deregulation 
of epigenetic parameter leads to initiation and progression of disease, notably cancer 
2
. 
Epigenetic footmark is also perceived in several other diseases such as cardiovascular 
disease 
5
, type-2 diabetes 
6
 and developmental syndromes like Prader-Willi, Angelman 
syndromes 
1,7
. 
 
1.1.2 Epigenetic modification  
 
Epigenetic changes include DNA methylation, histone modifications and microRNA 
(miRNA) mediated gene silencing, all of which are vital mechanism known to regulate 
gene expression
7,8
. There is a close relationship between histone acetylation and DNA 
methylation and thereby chromosomal remodeling as shown in the Figure 1 . When 
CpG island in a gene promoter becomes hyper methylated this coincides with 
deacetylation of local histones. Alternatively hyper acetylation of histone predisposes to 
methylation of target DNA. 
9
 
 2 
 
 
Figure 1. Heritable gene silencing due to interaction between RNA, DNA methylation 
and histone modification. Histone modification can also initiates CpG methylation by 
attracting DNA methyltransferase, which in turn can induce histone modification 
pattern involved in gene silencing as shown by double arrow. 
 
1.1.2.1 DNA methylation 
 
The best studied epigenetic alteration is DNA methylation. The mechanism of 
methylation is transfer of a methyl group from S-adenosylmethionine to the 5-carbon 
position of cytosine by an enzyme known as DNA methyltransferase (DNMTs) as 
shown in Figure 2 below. DNA methylation has important roles in gene expression by 
enrolling methyl CpG- binding protein. For example, DNA hyper methylation of tumor 
suppressor genes and recruitment of repressor complexes lead to chromatin 
condensation and thereby inactivation of gene 
3
. Hypo methylation of DNA is also a 
common event in cancer. Hypo methylation leads to activation of oncogenes or 
genomic instability which is also frequently observed in cancer 
1
. So far in human 
cancer, two sorts of DNA methylation have been studied: one is global hypo 
methylation due to overall loss of 5-methyl-cytosine and the other is promoter specific 
hyper methylation (CpG island specific) 
1,2
.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Diagram showing DNA methylation as a reversible procedure and the 
pathway of cytosine methylation/demethylation. Both methylated and unmethylated 
cytosine can be converted into thymine and thereby affecting mutation (C to T 
transition) that contributes to under-representation of cytosine in the genome. 
 
1.1.2.2 Histone modification 
 
Another important event in cancer is histone modification which is characterized by 
covalent alteration of N-terminal tail of core histones (H2A, H2B, H3 and H4). Most 
studied histone modification in cancer is acetylation. The enzyme responsible for 
histone acetylation is histone acetyltransferase (HATs) which acetylates lysine and 
arginine residues of histone tails leadings to an open chromatin structure so that 
transcription regulator can have access to promoter region and gene activation 
10
. 
Histone Deacetylase is another class of enzyme which takes away the histone acetyl 
groups and thereby prevents transcription as shown in Figure 3. Other histone 
modifications are methylation, phosphorylation, biotinylation and ubiquitination 
11-13
. 
Histone modification has a major role in initiation of cancer as well as progression of 
malignancy 
14
. 
Hydrolytic 
deamination 
 
Cytosine 
 
5-methyl 
cytosine 
 
Thymine 
 
 
Uracil 
DNA 
replication 
DNA methyl 
transferase 
        DNA 
demethylation 
Deamination 
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Figure 3. Role of histone acetyltransferase and histone deacetylase on activation and 
silencing of a gene, respectively. HAT adds acetyl to lysine residue and thereby takes 
away positive charge form the amino group and HDAC reverses the state. 
 
1.1.2.3 MicroRNAs (miRNAs or, miR) 
 
MicroRNAs are 20 to 30 nucleotide long non coding RNAs which has negative 
regulatory effect on target genes 
15
. After formation of mature miRNA, it is integrated 
into a compound known as RNA-induced silencing (RISC complex). RISC-miR 
complex can target mature RNA as shown in Figure 4. The  miRNAs targets CpG 
island of a promoter area, binds to the 3` untranslated region of target mRNA specially 
a number of protein coding transcript and thereby alters DNA and histone methylation 
or degradation of mRNAs which leads to post transcriptional down regulation of target 
gene 
16-18
 as shown in Figure 4. In a typical cell miRs are strongly regulated whereas 
deregulation of miRs leads to cancer 
19,20
. Not only in carcinogenesis, several studies 
have shown over expression of miRs as a basis for progression and metastasis of cancer 
as shown in Figure 5, for example when miR-21 is over expressed in breast cancer can 
stimulates metastasis into lung 
21,22
. A number of studies have revealed that miRs can 
be used as diagnostic and prognostic markers 
23
.  
 
  
 
Figure 4. Biogenesis and mechanism of action of miRNAs 
 
 
Figure  5. Function of deregulated miRNAs which may either re-expressed tumor 
suppressor gene or activate oncogene to cause excessive cellular proliferation, 
metastasis, and angiogenesis and inhibits apoptosis. 
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1.2  EPIGENETIC PROGRAMMING DURING CELLULAR 
DIFFERENTIATION 
 
During cellular differentiation certain genes need to be activated and while others need 
to be silenced to make correct cell lineage decision. Establishment of precise gene 
expression pattern is synchronized by epigenetic mechanism including histone 
acetylation and DNA methylation. 
 
1.2.1 Role of Histone Deacetylases in differentiation 
 
Genes involved in cellular differentiation processes in various tissues are regulated by 
Histone Deacetylases (HDACs) shown in Figure 6. Many studies have shown that 
HDACs inhibitors (HDACis) can modulate the differentiation of neuronal, epithelial, 
adipocyte, osteogenic, muscle cells and hematopoietic cells and in most of the cases 
HDACi induces terminal differentiation 
24
. 
 
In cancer, stability between proliferation and differentiation is disrupted: tumor cells 
often keep an immature phenotype by exhibiting altered or no differentiation and by 
showing limitless proliferation as shown in Figure 6. HDACi may restore the stability 
by stimulating differentiation of tumor cells and reverse their potential for proliferation. 
Acute myeloid leukemia in which myeloid differentiation is blocked, is an outstanding 
disease model to investigate the parameter of differentiation and cancer progression 
25
.  
Not only in hematological malignancy, several studies have shown a role of  HDACi in 
differentiation of glioblastoma cells 
26
, in breast cancer cells 
27
 , hematoma cells 
28
, 
endometrial stromal sarcoma 
29
 and small cell lung cancer cells 
30
. 
Most of the studies have been shown that HDACs cause blockage of differentiation as a 
hallmark of cancer and HDACi reestablishes it. In neuroblastoma a particular HDAC 
named HDAC8 has been shown as a vital regulator of tumor cell differentiation 
31
. 
Progression of neuroblastoma is associated with high HDAC-8 expression. By 
knocking down HDAC-8 or treating with HDACi reserves cellular proliferation and 
stimulates neuronal differentiation, which emphasizes HDAC-8 as a promising target of 
differentiation therapy 
31
.  
 
Although little is known about HDACi to specific HDACs, a HDAC8-selective 
inhibition by siRNA 
31
 has been shown to induce neuronal differentiation and inhibition 
  
of proliferation in neuroblastoma cells. A study has also shown that HDAC2 
knockdown causes apoptosis in the same cell, which suggest that distinct cellular 
programs are regulated by different HDACs 
31
. 
 
 
 
Figure 6. Role of histone deacetylases in cellular differentiation, proliferation, 
apoptosis and migration/metastasis. 
 
 
 
1.2.2 HDAC inhibitors (HDACis) on cellular differentiation 
 
HDACis are novel classes of drugs that function by epigenetic remodeling and thereby 
lead to changes in expression of target genes which are involved in regulation of cell 
cycle, apoptosis, proliferation and differentiation. Most often it causes reactivation of 
certain genes like p
21
 
28,32
. HDACi stimulates Cyclin-dependent kinases (Cdk)/Cyclin 
complexes which are responsible for Retinoblastoma (Rb) protein phosphorylation and 
thereby arrest of G1 phase of a cell cycle which ultimately arrest cell cycle at S phase 
and DNA replication as shown below in Figure 7. 
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The mechanisms include:  
 
 HDACi causes up regulation of genes transcript that controls G1/S phase 
progression,   most important is Cdk inhibitor CDKN1A (p21) 
33-35
. 
 
 HDACi at high concentration causes hyper acetylation and thereby G2 phase 
arrest. Cell lines that are arrested in G2 phase are resistant to the cytotoxic 
effects of these drugs. If the effect of HDACi on G2 phase arrest is lost, cells go  
           into mitotic phase and become sensitized to apoptosis by these drugs. 
36-38
 
 
 When cells enter aberrant mitosis, a system known as spindle assembly 
checkpoint (SAC), arrest cells into mitosis until defects are repaired. If repair 
cannot be achieved within > 16 hrs then apoptosis is triggered which indicates a 
selective cytotoxicity action of this drug. 
36,39,40
 
 
HDACi have been tried for the treatment of varied disease like autoimmune disease 
41
, 
muscular dystrophies, inflammation 
42
, immune disease 
34
, neurodegenerative disease 
43
 
and latest as anti-HIV agents 
44
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Schematic diagram showing possible mechanism of action of HDACi on cell 
cycle and differentiation. Treatment with HDACi induces acetylation of histones and 
non-histone proteins thereby inducing two distinct downstream pathway activations. 
HDACi at high concentration causes hyper acetylation of histones which modulate 
expression of subsets of genes responsible for cell cycle arrest, differentiation and 
apoptosis. Hyper acetylation of histones also induces a G2 cell cycle checkpoint, a 
phase that is lacking in cancer cells, and a reason of aberrant mitosis in cancer. 
HDAC 
inhibitors 
 
HDACs 
Acetylation of 
Histone 
Acetylation of on-
histone 
Cytoskeleton Transcription Check point 
 Cell cycle arrest • Differentiation • Apoptosis • Cell migration 
 G1 S G2 M G1     
HDACi 
 
Cytostatic 
HDACi 
 
Cytostatic Resistant 
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1.2.3 DNA methyltransferase and cellular differentiation 
 
DNA methylation is a hallmark of genomic imprinting and regulates gene expression 
and cellular identity. In human, there are three active DNA methyltransferases 
(DNMTs) named DNMT1, DNMT3A and DNMT3B. DNMT3A and DNMT3B are de 
novo enzymes  associated with establishment of DNA methylation during development 
while the maintenance DNMT1 is in charge of methylation of newly synthesize DNA 
strand to preserve the epigenetic regulatory state after cellular replication 
45,46
. In 
addition to these there is another DNMT which is catalytically inactive known as 
DNMT3L, which stimulates the function of DNMT3A-and -3B and suppress gene 
expression after association with HDACi 
47
. 
During embryonic development, multipotent and pluripotent cells can differentiate into 
hundreds of distinct type of cell types and DNA methylation plays a major role to 
maintain differentiated states by silencing of responsible gene for differentiation. 
To preserve stem cell pluripotency, DNMT1 and other DNMTs are not continuously 
required to suppress differentiation and thus maintain the pluripotency. By regulating 
cell cycle and DNA repair pathway, DNA methylation maintain cellular differentiated 
states. Such as in epidermis and hematopoietic tissues, deficiency of DNMT1 prevents 
cellular proliferation, self-renewal and premature differentiation. Extensive changes in 
DNA methylation is observed only in progenitor cells of normal epidermal 
differentiation along with normal expression of DNMT1 whereas differentiated cells do 
not show such type of methylation changes 
48,49
. Knockdown of DNMT1 in 
undifferentiated epidermal progenitor cells lead to cell cycle arrest, premature 
differentiation and a failure of tissue self-renewal. Loss of DNMT1 is associated with 
de-repression of genes responsible for differentiation and loss of cell cycle progression 
gene which specifies the importance of DNA methylation and DNA binding protein for 
maintaining of progenitor states and thereby inhibits differentiation 
48-50
. 
DNA methylation also has vital role in regulating cellular multipotency (rapidly self-
renewal ability). Such as DNMT1 regulates cell cycle by suppressing p15INK4B
 
and 
p16
 INK4A
. Deletion of DNMT1 is associated with loss of proliferative stamina which is 
partially rescued by Cyclin D1 and Cdk4 expression 
51,52
. 
This study has also shown that after addition of Gadd45 A/B in demethylation of DNA 
causes active cellular proliferation, differentiation and methylation of specific 
differentiation promoters as shown in Figure 8. 
  
 
 
Figure 8. Figure showing role of DNMT1 in regulation of DNA methylation in somatic 
progenitor differentiation. On left, in un-differentiated progenitor cells, DNMT1 along 
with its physical binding partner UHRF1suppress expression of differentiation gene, 
thereby repress differentiation. In the differentiated states (right), DNMT1 is down 
regulated and mediator of active DNA demethylation specially Gadd45A/B protein 
promotes DNA demethylation which leads to promoter de-repression and thereby 
causes induction of differentiation. 
 
1.3 PROSPECT OF EPIGENETIC THERAPY 
 
Epigenetic changes are reversible which makes it different from genetic changes and 
this is the basis for expected benefits of epigenetic therapy. The object of this treatment 
principle is to reverse epigenetic changes, especially DNA methylation, histone 
modification and expression of miRNA target genes, which leads to carcinogenesis, 
and thereby to reestablish a normal epigenome. 
So far two groups of drugs have been reported that target the epigenome: DNA 
demethylating agent and HDACi. Both of them functions by re-establishing some 
functions, e.g. tumor suppressor gene expression, often aberrantly silenced in cancer 
tissue due to epigenetic mechanism. 
 
1.3.1  DNA methylating agent and epigenetic therapy in cancer 
 
Nucleoside analogs are available that inhibit DNMTs. These include 5-azacytidine (5-
aza CR) or Vidaza and 5-aza-2` oxycytidine (5-aza- CdR) which is known as 
Decitabine . The latter has been approved by the Food and Drug Administration (FDA) 
 12 
 
for treatment of selected hematological malignancies. Zebularine is another 
demethylating drug used for cancer 
53
. These inhibitors lower DNA methylation by 
inhibiting DNA methyltransferases and thereby cause re-activation of silent genes 
7,54
 
as shown in Figure 9.  
 
Figure  9. DNMTi reactivates aberrantly silent gene 
 
 
1.3.2 Histone modification therapy of cancer 
 
HDACi is a class of epigenetic drugs which inhibits the function of HDACs thereby 
removing acetyl group from histone tails. Valproic acid and the suberoylanilide 
hydroxamic acid (SAHA) or Vorinostat, are two currently available HDACi which acts 
by inhibiting class I HDACs (HDAC1-3 and HDAC8) and class II HDACs (HDAC4-7, 
HDAC9 and HDAC10). 
7
  These drugs affect cancer cells by increasing expression of 
differentiation markers, influencing cell cycle and inducing of apoptosis 
55-57
, with less 
toxic effect on normal cells 
58,59
. Anticancer effects of HDACi are through 
transcriptional changes. HDACi can arrest cell cycle progression (Figure 10) by 
blocking at multiple points mainly in G1, G2 and mitosis. At present HDACi is in 
clinical trial either in combination with other drugs or as monotherapy. For example, 
Vorinostat is approved for the treatment of cutaneous T-cell lymphoma and is an 
example of principles for future cancer therapy 
60,61
. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    
                     Figure 10. Effects of HDACi in human cancer 
 
 
1.3.3 MicroRNAs as a therapeutic targets 
 
MicroRNA- centered therapy has been proposed for the treatment of cancer, either 
alone or combination therapy. Therapeutic aspect of miRNAs is based on its ability to 
target multiple cellular events such as proliferation, differentiation and survival. MiR-
181 has been shown to be a target for T cell receptor sensitivity. MiR 15a/16-1 has 
been studied for leukaemic MEG01 cell apoptosis and also for inhibition of tumor 
growth in a xenograft model. So far, two key approaches have been used to target 
miRNA expression in cancer. One is a direct method in which oligonucleotide or virus 
vectored miRNA is used to halt the expression of oncogenic miRNA and another is 
indirect method in which tumor suppressor miRNA that has been lost in cancer, is 
restored. 
23
 
 
Apoptosis Anti-angiogenesis 
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Cell-cycle arrest/ 
Differentiation 
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1.4 INSULIN LIKE GROWTH FACTOR 2 (IGF2) 
 
Key genes of the IGF2/H19 locus are Insulin like Growth Factor 2 (IGF2) and H19. In 
our study we have emphasized on IGF2 and its role in cancer development. Human  
IGF2 gene is located on the short (p) arm of chromosome 11at locus 15.5 and extends 
30 kb 
62
. The gene product, the IGFII protein, is fully processed, 67 amino acids 
63
. 
IGF2 is located close to the insulin gene  and < 200 kb away from H19 gene 
63-65
. 
 
 
 
 
 
 
 
 
Figure 11. Human chromosome 11showing position of IGF2/H19 locus 
The Human  IGF2 gene consists of nine exons and five different promoters numbered 
as P1, P0, P2 - P4, creating transcripts with common coding sequences at exons 7,8 and 
part of 9 
66
 (Figure 12). The different transcript produced by the IGF2 gene and the 
putative transcription factors for the promoters are shown in table1. 
 
P1 is the main promoter of IGF2 transcription in human postnatal and adult liver. Its 
transcript and transcription factors are shown in Table 1.
67
. 
The P2 transcript is 5.0 kb 
68
 and lowly abundant in human fetal and adult tissue with 
some rise in human tumor tissue 
69
. 
The P3-promoter produces 6.0 and 2.2 kb mRNAs 
67
 expressed in fetal and mature non 
hepatic tissues and in most IGF2 expressing cell lines. This promoter contains a 
functional TATA box and a CAAT-box. The distal promoter region (-1300/-289) is 
responsible for cell type specific IGF2 expression. In Hep 3B and HeLa cells 
expression occurs from the proximal promoter region 
70
. 
 
11 p15.5 
 
 
  
Name P1 P0 P2 P3 P4 
Expression Post natal 
and adult 
liver 
Placent
a All 
adult 
tissues 
except 
brain 
and 
fetal 
skeletal 
muscles 
Fetal 
tissue, 
some 
cancer 
(low) 
Low 
amount in 
some 
adult 
tissues. 
 
Fetal tissues 
and cancer 
tissues 
Fetal 
tissues 
and 
cancer 
tissues. 
Low 
amount in 
some 
adult 
tissues. 
 
Transcript 
(mRNA) 
5,3 kb 5kb 5.0kb 6.0kb 
(abundant) 
2.2 kb (minor) 
4.8kb 
Transcription 
factors 
Sp1, 
C/EBPα, 
C/EBPβ,  
HNF-3β 
HNF-4 
(repressor) 
RAR 
RXR 
(TATA 
less 
promoter) 
 No 
transcripti
on factor, 
Weak 
promoter 
without 
TATA or 
CAAT 
less 
promoter 
TBP(TATA 
binding 
protein) 
p53 (repressor) 
CTF(CAAT 
transcription 
factor) 
Sp1 
Egr-1(+++) 
Egr-2 
WT(repressor) 
 
Sp1 is 
major 
regulator 
of P4, 
Egr-1 
RB 
 
Table 1.  IGF2 promoter specific transcripts and its transcription factors 
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Figure 12.  Structural anatomy of human IGF2 gene. Nine exons are shown by boxes 
numbered as 1-9. Common coding regions are marked by orange colored boxes. Five 
promoters are numbered P1, PO,  P2-P4 and transcription starts sites are indicated by 
arrow. 
 
Insulin like growth factors (IGFs) are potent mitogen for cellular growth and 
differentiation.  IGFs that are locally produced, have important role in wound healing 
and regeneration. In human serum IGFII levels range from 100ng/ml to 300 ng/ml from 
week 30 to term pregnancy respectively.  After birth serum level of IGFII increases up 
to 700 ng/ml. During embryonic period, IGF2 transcripts are produced by P2, P3 and 
P4, among which the P3 producing 6 kb mRNA is the most active one. The activity of 
these promoters goes down after birth within the first year of life 
71
 . Subsequently, P1 
promoter becomes activated and its 5.3 kb transcript is the main IGF2 encoding 
transcript from first year to adult liver.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1.5  GENOMIC IMPRINTING  
 
 
 Genomic imprinting is a biological phenomenon affecting gene expression and which 
is under epigenetic control, in which one allele is differently expressed depending on 
parent of origin 
72,73
.  It has been shown that mouse embryo cannot develop normally if 
both alleles are either only of paternal or maternal sources. This verifies that to have a 
complete viable embryo both parental contributions is required 
74,75
. Equal parental 
contribution is also vital for development of the human embryo e.g. hydatidiform molar 
pregnancy is an androgenous embryo which lacks maternal genome 
76,77
. As a result it 
does not turn into viable fetus. Conversely, ovarian teratoma is grown due to 
spontaneous duplication of an ovarian oocyte, lacking paternal genome 
78
. Studies have 
shown that mice with balanced translocations containing small genomic regions 
originating only from the father or mother, is able to develop into mice embryo (UPD). 
This reveals the restriction of biparental inheritance to certain area of genome 
79
. These 
positions have been shown to harbor clusters of imprinted genes. The first imprinted 
gene discovered was the murine Igf2 
80
 . In 1993 also the human IGF2 gene was shown 
to be imprinted 
81
. Genomic imprinting has likely an important role in preventing 
parthenogenesis and Parthenogenic mice die within 10 days of embryogenesis. The 
imprinted IGF2/H19 locus has key role in this since genetic manipulation of it can 
allow for a viable mouse fetus with two maternal genomes. 
82
. 
So far 100 imprinted genes have been recognized in human and mouse genomes. Most 
of the imprinted genes remain in clusters 
83
 which are rich in CpG islands 
84
. Imprinting 
is erased just after fertilization, reprogrammed and then reset again during 
gametogenesis 
72,83
. In mammals 80% the imprinted genes are located in clusters or 
closed proximity to each other 
72,73
. A gene is termed imprinted when its expression is 
suppressed due to parent of origin. Interesting examples of two diverse disorders that 
can progress due to the loss of the same genetic segment of chromosome 15 are Prader-
Willi and Angelman syndromes, which arise specifically depending on parent who 
donates the deletion 
85
.  
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1.5.1 The IGF2/H19 mechanism for genomic imprinting 
Imprinted genes are placed in clusters and most of the time they share common 
imprinting control regions (ICR), also called differentially methylated regions, (DMR). 
The cluster of imprinted genes located on 11p15.5 locus includes IGF2, H19, CDKNIC, 
KCNQ1 and KCNQ1OT1. The cluster is distributed into two domains. One domain 
controls expression of imprinted genes IGF2 and H19 and located at the end of the 
telomere and known as the IGF2/ H19 locus, Figure 13. Another domain is located 
proximal (towards centromere) to the IGF2/ H19 locus and controls the imprinting of a 
number of genes together with CDKN1C (Cyclin dependent kinase1), KCNQ1 (a 
voltage gated channel1) and KCNQ1OT1 (antisense RNA). Disorder of 11p5.5 
imprinting region leads to two imprinted clinical phenotype: Beckwith-Wiedemann 
syndrome (BWS) and Silver-Russel syndrome (SRS). 
86,87
 
 
Figure 13. Imprinted gene clusters at IGF2/H19 locus 
 
IGF2 is a maternally imprinted and H19 is a paternally imprinted gene located in the 
IGF2/H19 locus. At DMRs, methylation of the two parental alleles is different 
depending on the parent who donated the allele. An important feature of  epigenetic 
marks in DMRs is they are erased during gametogenesis and re-established in 
primordial germ cells to replicate parental characteristics for the subsequent generation 
88,89
.  DMRs regulate imprinting by enrolling or inhibiting binding of an insulator at the 
methylated or un-methylated CpGs in the DMR. The DMR at the IGF2/H19 locus is 
one example of this. The H19 DMR is situated just upstream to H19 (around 2 kb) and 
downstream to IGF2 and this is the site for binding of the zinc-finger protein CCCTC-
binding insulator factor CTCF. On the maternal allele, CTCF binds the H19 DMR 
when it is un-methylated, thereby insulating the IGF2 promoter from the IGF2/H19 
common enhancer located downstream of H19 as shown in Figure 13. This makes the 
  
enhancer to interact with H19 promoter thereby causes expression of H19 whereas 
IGF2 expression is silenced. In contrast, the H19 DMR on the paternal allele is 
methylated which prevents CTCF to bind thereby allowing the IGF2 promoter to 
interact with the H19 downstream enhancer and IGF2 expression. Additionally the 
methylation of the DMR on the paternal allele is spreading into the H19 promoter, 
thereby repressing it. 
90,91
 
 
1.5.2 Loss of imprinting of IGF2, LOI 
 
Pathogenic modification of DNA methylation without change in the DNA sequence is 
known as epimutation. Mutation or epimutation can both be involved in imprinting 
disorders (see e.g. Prader-Willi and Angelman as mentioned above). Common 
mechanism of imprinting disorder are: (i) Uniparental disomy (UPD), (ii) copy number 
variation that directly change imprinted gene function and (iii) mutation or epimutation 
at DMR/ICR that results in biallelic expression  of imprinting genes. 
83,92,93
. Biallelic 
expression of IGF2 is known as loss of imprinting (as shown in Figure 14), LOI of 
IGF2 which can be either due to reactivation of already silent maternal allele or 
duplication of the active paternal allele (UPD). 
Indeed BWS and SRS, LOI of IGF2 is observed in several human cancer e.g. Wilms' 
tumors 
94
, colorectal carcinoma 
95
 and ovarian cancer 
96
. Somatic epimutation is the 
cause of LOI of IGF2 in both sporadic embroynal tumor e.g. Wilms` tumor or sporadic 
adult neoplasia like colorectal cancer, chronic myeloid leukemia, ovarian carcinoma, 
renal cell carcinoma, lung adenocarcinoma, esophageal cancer, meningioma’s, 
hepatoblastoma, osteosarcoma, skeletal muscle tumor and some other cancers 
97
. 
Precancerous conditions like colonic polyps and development of nephrogenic rest in 
kidney present with high IGF2 expression due to LOI. This stimulates autocrine and 
paracrine growth and leads to cell hyperplasia and cellular proliferation 
98,99
. In some 
colorectal cancer patients LOI of IGF2 has been detected in adjacent normal tissues and 
also in blood which is suggestive of blood IGF2 as a biomarker for colorectal cancer 
100
. A study has also shown partial LOI of IGF2 in normal individuals, which is 
inherited down the generations 
101
. Cruz-Correa et al has shown that LOI of IGF2 is not 
age related but instead it is a stable epigenetic phenomenon 
102
. 
H19 is recognized as a tumor suppressor gene, the transcript of which is a noncoding 
RNA. H19 DMR is hypo methylated in bladder cancers 
103
 and LOI of H19 with 
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biallelic expression has been publicized in lung cancer by Kondo et al, 1995 (abstract). 
The H19 locus also harbors the microRNA, miR-675 
104
.  
 
 
 
                            Figure 14. Mechanism of LOI of IGF2 
 
 
 
 
 
 
  
1.6   PLAG1- MECHANISM IN CANCER 
Pleomorphic Adenoma like gene1 or PLAG1, is a proto oncogene with location to 
long arm of human chromosome 8, (8q12)
105
. The PLAG1 protein is a zinc finger 
transcription factor with nuclear localization which has an important role for normal 
development of the salivary gland
106,107
. During different types of oncogenesis 
PLAG1 becomes re-activated. Chromosomal rearrangement is the cause of re-
activation of PLAG1 and thus overexpression in different types of cancer. There are 
two frequent translocation, t (3:8) (p21; q12) shown in Figure 15 and t (5; 8) (p13; 
q12). This leads to replacement of the normally inactive PLAG1 promoter with the 
active promoters of β-catenin (CTNNB1) or leukaemia inhibitory factor receptor 
(LIFR) genes
108
. This results in over expression of PLAG1 in tumour cells and thus 
deregulation of target gene thereby causing excessive cellular growth and 
proliferation. One of the PLAG1 target genes is IGF2 
107
 and overexpression of 
PLAG1 is associated with increased IGF2 expression from its P3 promoter  in various 
cancers  like hepatoblastoma 
109
, lipoblastoma 
110
, and leukaemia 
111
, although 
PLAG1 was first discovered in pleomorphic adenoma of the salivary gland 
112,113
. 
Other PLAG1 target genes are Cytokine-like factor-1 (CRLF1), Bone derived growth 
factor (BPGF-1), Choriogonadotropin beta chain (CGB), Vascular endothelial growth 
factor (VEGF) and Placental growth factor ( PIGF) 
105
.  
 
 
 
 
 
 
 
Figure 15. Translocation of the β catenin promoter with PLAG1 promoter. 
 
8 q12 
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β-Catenin 
PLAG1 
 22 
 
Recent studies have shown that the transcription factor PLAG1 is a main target for 
deregulated miRNAs in Chronic Lymphocytic Leukaemia (CLL). Pallasch et al, 2009 
revealed that six miRNAs named as miR-181a, miR-181b, miR-107, miR-424, miR-
155 and miR-141 are down regulated in CLL with associated PLAG1 deregulation
114
. 
Predicted microRNA binding site in PLAG1 is shown in Figure 16. 
 
 
Figure 16. Schematic representation of predicted mi-RNAs binding site at PLAG1 3` 
untranslated region (UTR). 
  
2 AIMS OF THE STUDIES 
 
The general aim of the study was to investigate epigenetic mechanism and regulatory 
features of human cancer and neural progenitor cells which may be used for diagnosis 
and therapeutic opportunities. 
Specific aims were: 
 
1. To explore the effect of HDAC inhibition on intercellular gap junctional 
protein connexin 43 (Cx43) between neural progenitor cells (NPCs) and 
glioblastoma multiforme cells to facilitate NPCs as a potential vector for 
glioblastoma treatment. 
2. To investigate epigenetic mechanisms induced by HDACi 4-phenyl 
butyrate on differentiation of human embryonic NPCs and its association 
with de novo DNA methyltransferase, DNMT3B. 
3. To examine the role of transcription factor Pleomorphic Adenoma Like 
Gene 1 (PLAG1) on IGF2 P3 promoter regulation in two different human 
cancer cell lines. 
4. To analyse the association of the proteomic profile with transcriptional 
aberrations at the H19/IGF2 locus, among two groups of adrenal tumours: 
adrenocortical adenoma (ACA) and adrenocortical carcinoma (ACC). 
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3. METHODS  
 
3.1  Immunocytochemistry (ICC) 
 
Immunocytochemistry is a microscopic technique which is used to  identify a target 
protein, peptide or other antigen (e.g. nucleic acids and their modifications, lipids) in 
cells (either cultured or cell suspension) by using a specific antibody, which binds with 
the target epitope (Figure 17) and thereby become visualized under microscope after 
various staining techniques 
115
. This is a useful tool for the detection of individual 
cellular contents 
116
. Except cultured cells, blood smears, aspirates, and swabs can also 
be used. Similar analysis of tissue sections is referred to as immunohistochemistry. The 
experimental procedure involves sample preparation, application of primary antibody, 
secondary antibody, staining and visualization under microscope. Sample preparation 
involves fixation, permiabilization of cell membranes, blocking procedures for 
avoiding  binding to non-specific epitopes, antibody binding and counter staining with 
Hoechst or DAPI. Depending on the type of cell used, the sample preparation is slightly 
different. The detection methods for visualization of antibody/antigen interaction can 
vary depending on sample type and detection limits. Direct detection (Figure 17, left) 
uses a single type antibody directed to the antigen in question, and can be conjugated 
with an enzyme such as horse radish peroxidase. During the detection phase, the 
sample is incubated with a solution where the peroxidase catalyzes a color reaction 
which can be observed under the microscope. An alternative and popular detection is to 
conjugate the antibody with a fluorophore, such as fluorescein or Rhoda mine for direct 
detection. Indirect detection (Figure 17, right), employs the same principles, but the 
primary antibody binding to the sample is targeted by a secondary antibody carrying 
the conjugated detection molecules. This method amplifies the signal substantially. In 
our laboratory we practice an indirect method which has been used for the first two 
papers in this thesis. 
After the detection steps, the sample slides are mounted with a coverslip with a drop of 
mounting medium to seal the sample. To prevent drying and movement under 
microscope, coverslip can be sealed with nail polish and slides can be stored in dark at 
minus 20 °C or +4 °C for microscopic examination. 
 
 
 
  
 
 
 
 
 
Figure 17.  Illustration of the basic principles for immunocytochemistry using direct 
and indirect detection.  
 
 
 
 
 
3.2   Western Blot (WB) 
 
Western Blot, (WB) or protein immunoblotting is a widely used technique to separate 
and label specific proteins for identification, size estimation and quantification, from 
tissue homogenates or cellular extracts. The proteins are separated by sodium dodecyl 
sulfate (SDS), polyacrylamide gel-electrophoresis (PAGE), followed by transfer of 
the separated proteins from the gel onto nitrocellulose or Polyvinylidene difluoride 
(PVDF) membrane and then immunoblotting of the specific protein with antibodies 
119
. The procedure involves sample preparation, gel electrophoresis, transfer of 
protein from gel to membrane, and immunostaining of the blot 
120
. The method starts 
by lysing of the sample to release and solubilize the protein allowing migration 
through a separating gel. However, when the lysis begins other alterations such as 
proteolysis, dephosphorylation and denaturation also take place. These events can be 
slowed down by keeping the samples  on ice or at 4 °C and by addition of enzyme 
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inhibitors to the lysis buffer 
121
. After protein separation using PAGE, the content of 
the gel is transferred to the membrane. The detection procedure involves an enzyme 
reporter similar to immunocytochemistry. Since the membrane readily binds proteins 
including antibodies, a blocking procedure to minimize this unspecific binding to the 
membrane first needs to be performed. This is usually done with solubilized skimmed 
milk solutions. As is usually done in ICC, a primary antibody directed to the protein 
of interest is first allowed to bind, followed by an amplification (several secondary 
antibodies bind each primary antibody) by secondary antibody conjugated with an 
enzyme reporter, most commonly horse radish peroxidase which can cleave a chemo 
luminescent molecule in the detection solution to create light. This can be detected by 
film or by sensitive CCD cameras 
122
. 
 
 
 
3.3   Polymerase Chain Reaction (PCR) 
 
PCR is a widely used technique for selective amplification of DNA 
123
. The method is 
highly efficient so that infinite copies can be made of the target sequences. The basic 
PCR was invented in 1983 by Kary Mullis 
124
 , and its many different applications have 
revolutionized molecular biology and medicine since it started to become widely used 
in the late 1980s. DNA can be directly amplified while RNA needs to be reversed 
transcribed to cDNA before PCR is applied. There are so many different protocols and 
applications resting on PCR, that it is not possible to bring them up here. However, the 
basic principles will be mentioned. PCR is used to amplify sequences for further use, 
e.g. for cloning purposes or for making DNA standards to be used in various 
applications. It is used for sequencing applications, for analyses of DNA single 
nucleotide polymorphisms (SNPs), and for quantification of nucleic acids, to mention 
the most obvious. In this thesis, PCR was used to identify and semi-quantify a 
restriction fragment length polymorphism (RFLP) in the IGF2 gene, and for the exact 
quantification purposes of various mRNAs. In the first case genomic DNA and cDNA 
(reversed transcribed from RNA) was used followed by regular PCR and visualization 
of products after agarose gel electrophoreses. In the 2
nd
 case where more exact 
quantification was needed, quantitative real time PCR (qPCR) was applied. For qPCR, 
special instruments are used where amplified products are continuously assayed during 
the amplification reactions.  
  
The conventional PCR reaction includes: target DNA; two primers of approximately 20 
nucleotides in length, one for each strand of the DNA; DNA polymerase; and the four 
nucleotides of DNA, adenine, guanine, cytosine, and thymine. For qRT-PCR, the  
master mix in addition also contain a DNA binding dye such as SYBR Green I or the 
reporter molecule which is a sequence-specific probe composed of an oligonucleotide 
labeled with a fluorescent dye plus a quencher (e.g. TaqMan® probes). 
The qPCR reaction includes three major steps which are repeated for 30 or 40 cycles - 
denaturation, annealing and extension (Figure 18). 
 
Figure 18. Schematic illustrations of the PCR method with 30-40 cycles of the three 
steps of denaturation, annealing and extension.  
 
The PCR reaction is carried out for 30-40 cycles in an automated cycler machine, 
which can accurately change the temperature in a very short time. Denaturation is 
carried out at 94 °C to generate single stranded DNA. During annealing the primer 
anneals or hybridizes itself to its target on the 5´ side of the DNA to be amplified on 
one of the strands. DNA polymerase then attaches to a primer template to extend the 
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primer. Polymerization starts when the reaction extents to correct temperature 
123
, 
whereby the enzyme adds nucleotides to a growing strand of DNA. Since both DNA 
strands are copied, the number of target copies will increase exponentially. If we start 
from one target copy, there will be two copies after the first cycle, followed by 4, 8, 16 
and so on
125
. This exponential phase is followed by a plateau phase due to consumption 
of the reaction components 
126
 (Figure19).  
The PCR result is analyzed in different ways depending on the application. Commonly 
the software provided with the real-time PCR instrument is used. In conventional PCR, 
the amplified products visualized by agarose gel electrophoresis. In real-time PCR the 
amplification product is measured during the reaction, i.e. in real time, whereby the 
product is quantified after each cycle. As illustrated in Figure 19,  the number of cycles 
is plotted against the fluorescence , which is proportional to the amount of amplified 
product.
126
  
PCR is used to analyze DNA and gene expression and has applications for basic 
scientific as well as medical questions. Studies of evolution, human disease, 
identification of criminals are some examples of fields relying on PCR. PCR can be 
applied to study DNA from all sources, such as detection of HIV in human blood 
samples.  
  
 
Figure 19. Amplification by real-.time PCR. The number of PCR cycles is shown on 
the x-axis, and the fluorescence on the Y-axis. The exponential phase and the non-
exponential plateau phase are shown. The Ct value refers to number of cycle at which 
amplification plot crosses the thresh hold line and the threshold line is a horizontal line 
drawn at the amplification plot. When threshold line is crossed by amplification plot 
then it indicates ct value. 
3.4 Chromatin Immunoprecipitation (ChIP) 
Chromatin immunoprecipitation (ChIP) is used to determine whether a specific protein 
binds to or is localized to a specific DNA sequence
127-129
. The mains steps of the 
method are outlined in Figure 20. ChIP has been widely used for studying chromatin 
remodeling, mapping the position of modified histones, transcription factors, and other 
nonhistone proteins in the genome. In a conventional ChIP, DNA and proteins are 
reversibly cross-linked to maintain the association of proteins with target DNA 
sequences. The chromatin is then sheared by sonication to achieve fragments of 200 
~500 bp. Large complexes are removed by centrifugation, and the supernatant is used 
for immunoprecipitation. In native ChIP (nChIP), which is e.g. used for mapping 
histones to specific sequences, crosslinking is omitted and the natural binding between 
histones and DNA is exploited 
129
. Instead of sonication, micrococcal nuclease is used 
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to cut the DNA in between the histone containing nucleosomes. A specific antibody 
conjugated with e.g. a biotin is then used to bind the protein-DNA complexes. 
Streptavidin conjugated magnetic beads, or columns are then used to capture the biotin-
protein complexes. The immune precipitated complexes are washed, cross linking (if 
used) is chemically reversed, proteins are digested and the DNA that is left is collected. 
The DNA can be directly quantified by qRT-PCR or stored at -20 
0
C for up to 1 to 2 
weeks 
127
. The captured sequences can be amplified by qRT-PCR (ChIP-PCR) 
128
, 
cloning and high-throughput sequencing (ChIP sequencing) 
130
 or, hybridization to 
microarray (ChIP-chip) 
131
. For ChIP-PCR used in this thesis, all ChIP samples are run 
in triplicate and then mean quantities are used for all subsequent analysis. 
 
Figure 20. The main steps of the ChIP procedure. 
 
  
 
3.5   LUMINOMETRIC METHYLATION ASSAY (LUMA) 
 
LUMA is a global DNA methylation analysis method that is based on the use of 
methylation sensitive and resistant restriction enzymes, and quantification by 
Pyrosequencing of amount of cleavage in the genome in relation to an internal standard. 
LUMA uses two isoschizomer enzymes for the sequence CCGG, HpaII or MspI, to cut 
genomic DNA. HpaII will only cut if the internal cytosine is un-methylated whereas 
MspI will both methylated and un-methylated DNA. Both leave a 5´ overhang. The 
EcoRI restriction enzyme is used in all reactions to normalize between the HpaII and 
MspI runs. The amount of restriction cleavage is then quantified by Luminometric 
polymerase extension assay where the overhangs created are filled in while producing a 
peak of light which is proportional to the number of cuts. DNA methylation is 
expressed as the relative ratio of HpaII / MspI normalized to EcoRI. Theoretically, the 
ratio should be 1.0 if DNA is completely unmethylated, and should approach 0 when it 
is completely methylated. 
The basic phases of the LUMA technique and the nucleotide dispensations are 
illustrated in Figure 21. 
 
Figure 21.  Illustration of the LUMA method.  
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An example of how to analyze the data from LUMA is shown in Figure 22.  All 
overhang generated by EcoRI is completed by addition of first dATPαS which provides 
A peaks and then dTTP which create the T peak. The C+G peak represents ratio of cuts 
filled by MspI or HpaII. The final C+G peak represents any non-complete filling-in, 
and can typically be seen if the analyzed DNA was degraded. In the case shown the 
methylation in CCGG sequences is determined to be 57% (1-0.9/2.1).   
 
 
 
                                                                                              
     Figure 22.  Example of results from LUMA. From Karimi et al, 2006; Epigenetics 
 
 
 
3.6   DETECTION OF GENOMIC IMPRINTING 
 
Genomic imprinting means that a specific allele is marked in a parent of origin fashion. 
Functional genomic imprinting means that this mark has consequences for gene 
expression in allele-specific way
132,133
. This can be analyzed and quantified. Loss of 
genomic imprinting (LOI) is an event where the normally silenced allele is reexpressed 
together with the normally active allele. Thus a mono allelic to biallelic expression of a 
gene occurs. Insulin-like Growth Factor 2 (IGF2) is a maternally imprinted gene and 
LOI of IGF2 has been shown in many different cancers. Due to activation of the 
normally silent maternal allele both alleles of IGF2 are expressed which theoretically 
would double the gene dosage
100
.  
The principle for analyzing allele-specific expression is to exploit natural restriction 
length polymorphisms (RFLPs) generated by single nucleotide polymorphisms (SNPs) 
in restrictions sites present in gene exons. In this way, parental origins can be 
  
determined if the parents’ DNA is available and if paternal and maternal DNA is 
homozygous for different SNPs. If RFLPs exist, simple cutting of a PCR amplified 
product spanning the cutting site may be employed, followed by gel electrophoresis to 
separate the generated differentially sized bands. If the parents’ alleles are different, an 
offspring’s parental alleles can be traced back. It is thus necessary that in an individual’ 
both alleles carry different polymorphisms at a specific site in order to distinguish 
them. To analyze the expressed alleles, cDNA is generated and cut with the same 
enzymes. If only one allele is expressed, only the cut or   uncut band will be present, 
and if the parental type of allele is known it may be possible to determine which 
parental alleles is being expressed.   
 
 
Figure 23.  Detection of loss of imprinting (LOI). In this example paternal allele 
contains a single nucleotide polymorphism (SNP) that is recognized by ApaI restriction 
enzyme but maternal allele lacks this site (but in fact any allele can contain SNP). 
Oligonucleotide primers Oligo-2 and Oligo-3 can only amplify genomic DNA (gDNA) 
while Oligo-1 and Oligo-3 can only amplify cDNA or RNA. In example 3 & 4 gDNA 
shows both paternal and maternal allele marked as informative (In). These informative 
samples are run for RT-PCR with cDNA and digest with ApaI or EcoR1 which can 
detect only allele that contains  ApaI restriction site. In this example expressed allele is 
paternal and silent allele is maternal. 
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In most clinical cases however, the parental origin of a particular allele type is not 
known. Nevertheless, it may still be possible to determine mono- or bi-allelic 
expression if the individual is heterozygous for the RFLP 
134
. For IGF2, an ApaI RFLP 
in exon 9 is commonly used to distinguish alleles
100
. If genomic DNA analysis shows 
that both allele types are present, those are considered as informative samples which 
can be used for analysis of cDNA. The informative samples are run for specific RT-
PCR amplification of a cDNA template. The primer for the RT-PCR is usually placed 
in different exons, so that it is possible to distinguish cDNA from contaminating 
genomic DNA. Digestion of the RT-PCR product with ApaI restriction enzyme 
followed by agarose gel electrophoreses can then detect cut and uncut transcripts. In the 
case of monoallelic expression, the cut or uncut band only, will be present. In the case 
of biallelic expression, both the cut and uncut bands will be shown on the gel. The 
method is outlined in Figure 23. 
 
 
 
 
  
4.  RESULTS AND DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
The purpose of this study was to investigate the effect of HDAC inhibitor, 4-PB on 
inter-cellular communication through the gap junctional protein connexin 43 (Cx43) 
between neural progenitor cells (NPCs) and glioblastoma multiforme cells. Cx43 is an 
intercellular junctional protein which may facilitate transfer of therapeutic molecules 
between cells. This will enhance the employment of NPCs as a potential delivery 
vehicle for glioblastoma therapy. 
For this purpose we have used two NPC cell lines, NGC-470 and HNSC.100, both of 
human embryonic origin and with neural precursor characteristics, and two established 
Glioblastoma multiforme (GBM) cell lines, U87MG and U343MGa. The NGC-470 
cell line was established by immortalization from ventral mesencephalon of a 7-week-
old human embryo by using a retroviral vector containing the v-myc oncogene. The 
human HNSC.100, embryonic forebrain-derived, was used as a reference cell line. 
 
Differentiation of NGC-407 cells 
Cells were grown with and without basic fibroblast growth factor (bFGF) and 
epidermal growth factor (EGF) which promoted proliferation and differentiation by the 
presence or absence of the mitogens, respectively. Almost all cells were strongly 
positive for the neural stem cell marker nestin, while <5% stained for the astrocytic 
marker GFAP and <1% was positive for the neuronal cell marker β-tubulin III. After 5 
days of differentiation, the majority of cells differentiated into astrocytes with GFAP 
expression. Nearly 10% of cells changed into neurons with positive staining for the 
neuronal marker β-tubulin III. 
 
 
4.1  
Paper I 
HDAC inhibition amplifies gap junction communication 
in neural progenitors: Potential for cell-mediated 
enzyme prodrug therapy. 
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Modulation of Cx43 expression by the HDAC inhibitor 4 phenyl butyrate, 4-PB 
 
ICC demonstrated increased Cx43 immunostaining both in intensity and peripheral 
distribution after adding 4-PB to cultures to proliferating and differentiating cells, with 
additional Cx43 expression in differentiating 4-PB treated cells in comparison to 
untreated cultures. Cx43 in differentiated cells was distributed along the plasma 
membrane of cell surface whereas proliferating cells showed highly polarized 
distribution independent of cell density with areas of patchy fluorescence in the 
cytoplasm as well as granular appearance on the cell surface. WB analysis of whole 
cell extracts distinguished three immunoreactive forms of Cx43, smaller non-
phosphorylated, larger phosphorylated and hyper phosphorylated (or total) form. After 
4-PB treatment, proliferating NGC- 407cells showed an increase in total Cx43 and a 
decrease in Ser 279/282-phosphorylated. However, total Cx43 in differentiating cells 
was lower both before and after treatment with 4-PB, in comparison to proliferating 
cells, although 4-PB increased both the total and Ser 368 phosphorylated forms. 
Interestingly, 4-PB changed the relative distribution of the two different phosphorylated 
forms to total Cx43 in different ways in proliferating and differentiating cells. In 
proliferating cells, the relative proportion of both phosphorylated forms decreased 
significantly, while in differentiating cells, only the Ser 279/282-phosphorylated form 
decreased. This may have functional consequences for gap junction communication. 
 
Functional gap junctional communication 
 NGC-407 cells were labeled with two fluorescent probes, lipophilic membrane-bound 
and non-transferable, Dil and a water soluble acetomethylic ester, Calcein, which can 
diffuse via gap junctions to neighboring cells. Double labeled NGC-407 cells were co-
cultured with unlabeled NGC-407 or U343MGa or, U87MG cells under two different 
conditions, with and without 4-PB pre-treatment. After 4 hours, 4-PB pre-treated 
proliferating NGC-407 showed a substantial increase in intercellular dye transfer into 
both U343MGa and U87 cells in comparison to untreated cells. This was evident under 
both proliferating and differentiating conditions. 
 
We conclude that HDAC inhibitor 4-PB increases gap junctional protein Cx43 in in-
vitro model and that the neural progenitor cell paradigm is promising for use as a 
delivery vehicle for enzyme prodrug therapy for glioblastoma treatment. 
  
 
 
Figure 24. Figure showing gap junction 
 38 
 
 
 
 
 
 
 
 
 
The purpose of this study was to explore the role of de novo DNA methyltransferase 
DNMT3B for neural stem cell differentiation and the effect of the HDAC inhibitor 4-
PB. 
For this purpose we used the human embryonic midbrain stem cells, NGC-407, which 
displays increased expression of DNMT3B in differentiating cells in comparison to 
proliferating cells. When these cells were treated with 4-PB, differentiation of both 
astrocytic and neuronal form were suppressed along with reduction in DNMT3B 
immunoreactivity in the cell nuclei. 
 
Effect of 4-PB on neuronal stem cell marker by Immunocytochemistry (ICC) and 
Western Blot (WB) 
 ICC showed that 4-PB treated NGC-407 cells under differentiating conditions preserve 
their neural stem cell marker, nestin, while no considerable change was seen in 4-PB 
treated proliferating cells. On the other hand, WB realized the presence of a short and 
long form of nestin in proliferating cells both before and after 4-PB treatment. On the 
other hand, 4-PB treated differentiating cells retained the long form of the neuronal 
marker while the short form degraded after 5days of differentiation. CD133, another 
stem cell marker, also showed significant up regulation in 4-PB treated differentiating 
cells in comparison to untreated. 
 
Effect of 4-PB on astrocytic and neuronal differentiation marker 
When NGC-407 cells are allowed to differentiate by removal of mitogen, astrocytic 
(GFAP) and neuronal (β-tubulin) markers are unregulated. However, simultaneous 
treatment with 4-PB, prevented the appearance of both these proteins indicating that the 
HDAC inhibitor inhibited both astrocytic and neuronal differentiation. This was also 
supported by the lack of development of cell processes and fine networks. 
 
4.2  
Paper II 
HDAC inhibitor 4-phenylbutyrate preserves 
immature phenotype of human embryonic midbrain 
stem cells: Implications for the involvement of DNA 
methyltransferase. 
 
 
 
 
 
 
 
 
  
Global DNA methylation assessment in NGC-407 cells by LUMA 
 
Differentiating NGC-407 cells showed increased global DNA methylation in 
comparison to the levels in proliferating cells. Upon treatment with 4-PB, global DNA 
methylation level was somewhat, but not statistically significant decreased in both 
proliferating and differentiating cells in comparison to untreated cells. 
 
Outcome of HDAC inhibitor 4-PB on DNA methyltransferase 
Proliferating untreated NGC-407 cells showed both long and short isoform of the 
maintenance DNA methyltransferase, DNMT1, by WB analysis. 4-PB substantially 
reduced the longer form while no change was seen in the shorter. However, upon 
differentiation the longer form completely disappeared while the shorter form 
increased. Treatment of the cells with 4-PB did not significantly alter this situation.  
The suggested function of DNMT1 is to maintain methylation through cell division. It 
appears that the longer form of DNMT1 is important for this function since it so 
prevalent in the proliferating cells, while the shorter form, abundant in differentiated 
cells, may not display the same mode of action. This finding was also supported by ICC 
which showed a more specific type of nuclear staining of DNMT1 in proliferating cells 
compared to differentiating cells. When cells were treated with 4-PB, DNMT1 
immunoreactivity showed a diverse pattern, even outside the nucleus in proliferating 
cells, without any obvious effect in differentiating cells. 
WB investigation did not show any change of DNMT3A protein level between 
proliferating and differentiating cells. However, differentiating cells showed increased 
level of DNMT3B compared to proliferating cells. 4-PB treated proliferating cells 
showed slight down regulation of DNMT3A but no change of DNMT3B as compared 
to differentiating cells. ICC demonstrated both perinuclear and cytoplasmic localization 
of DNMT3A with nuclear restriction for DNMT3B. In comparison to untreated 4-PB 
cells, immunoreactivity for both DNMT3A and DNMT3B was markedly reduced in 
proliferating and differentiating 4-PB treated cells. 
The result of this study supports the involvement of epigenetic events, like association 
of HDACs on human embryonic NGCs differentiation. Epigenetic mechanisms behind 
the effect of HDAC inhibitor, 4-PB may involve de novo methylation by DNMT3B, 
leading to prevention of astrocytic and neuronal differentiation, and thereby 
preservation of the immature phenotype.  
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Figure 25. Immunocytochemistry showing cells positive for nestin. 
 
 
 
 
 
  
 
 
 
 
The purpose of this study was to investigate the role of the transfection factor 
Pleomorphic Adenoma Like Gene 1 (PLAG1) on regulation of IGF2 P3 promoter 
activity in two different cancer cell lines. We also examined if PLAG1 can partially 
override the insulation of H19 ICR in cancer cells using a green fluorescent protein 
(GFP) reporter construct.  
Cell line and stable cell clones 
Hep3B and JEG-3 cell lines and a zinc inducible PLAG1 expressing stable clone from 
JEG-3 cells were used for this study. 
 
Quantitative real-time PCR (qRT-PCR) analysis of IGF2 and PLAG1 
We examined the endogenous level of IGF2 and PLAG1 expression in Hep3B and 
JEG-3 cells by qRT-PCR. Hep3B cells showed higher level of IGF2 (around 6-fold) 
and PLAG1 (almost 3-fold, but both at a very low level) expression in compare to JEG-
3 cells, by using GAPDH as the normalizing gene. After transient transfection with 
PLAG1 expression vector, IGF2 and PLAG1 expression was analyzed in these two cell 
lines. Although Hep3B cells showed 2,000-fold induction of PLAG1 mRNA only a 
modest increase was found in IGF2 expression. The JEG-3 cells showed 130-fold up-
regulation of PLAG1 mRNA (from a very low level) but without any effect on IGF2 
expression. 
 
Chromatin Immunoprecipitation (ChIP) analysis 
To investigate the binding of PLAG1 to the IGF2 P3 promoter, we performed ChIP in 
Hep3B and JEG-3 cells. For this purpose cells were transiently transfected with a 
PLAG1 expression plasmid. Transiently transfected Hep3B cells showed increased 
binding of PLAG1 to IGF2 P3 promoter compared to control non transfected cells. 
JEG-3 cells however, showed no PLAG1 binding, neither in non-transfected cells, nor 
4.3  
Paper III 
Cell type and context-specific function of PLAG1 
for IGF2 P3 promoter activity. 
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in transfected cells. The additional expression of PLAG1 by transient transfection did 
not increase the endogenous level of IGF2 in JEG-3 cells. 
 
IGF2 P3 promoter driven reporter constructs expression in the presence of a 
functional insulator 
 
The ChIP assay showed that increased PLAG1 expression did not result in binding to 
the P3 promoter in JEG-3 cells, but did so in Hep3B cells. Furthermore, IGF2 
expression was not elevated in JEG-3 cells although their WT expression was very low. 
We therefore hypothesized that Hep3B and JEG-3 cells might have different sensitivity 
to the important H19 upstream insulator and that PLAG1 might be involved in this 
regulation. In order to get a clue, we started to investigate the insulator effect of the ICR 
in these two cell lines. We used an IGF2 P3 promoter driven GFP based reporter 
constructs containing the ICR with or without a SV40 enhancer. These constructs were 
first tested in both Hep3B and JEG-3 cells together with a RSV-driven red fluorescent 
protein (RFP) vector as a control, using both confocal microscopy as well as FACS 
sorting. It was evident that the Hep3B cells were insensitive to the insulator in contrast 
to the JEG-3 cells. We therefore analyzed the insulator effect in JEG-3 cells with a Zn-
inducible PLAG1 expression vector, using both confocal microscopy as well as FACS 
sorting to find out whether the ICR could be overcome by PLAG1. The outcomes of 
these experiments suggest that the insulator function in the construct is partially 
overridden by PLAG1 expression in this system. 
Since the ICR displayed different effects in the GFP-constructs depending on cell line, 
the GFP reporter constructs, driven by the IGF2 P3 promoter and containing the H19 
imprinting control region (ICR) insulator was transfected into both cell lines chromatin 
conformation assays of the ICR was conducted using DNase I hypersensitivity. The 
results suggest that the chromatin conformation of the transfected ICR was similar in 
both Hep3B and JEG-3 cell line.  
 
PLAG1 expression attenuates the insulator function of the H19 ICR 
In order to answer the question if PLAG1 over expression in JEG-3 cells could evoke a 
similar effect as in Hep3B, we generated a stable zinc-inducible PLAG1 clone in JEG-3 
cells. These cells were co-transfected with the GFP and RFP (control) constructs and 
analyzed by qRT-PCR. Although the enhancer containing, insulator-less construct pA-
GFP showed substantially higher GFP expression after 48 hours Zn induction in 
  
absolute numbers, the insulator-containing construct increased a similar-fold by Zn-
induced PLAG1 expression. This suggests that the insulator function is lost to some 
extent in JEG-3 cells by PLAG1 overexpression.  
Finally, we suggest that the PLAG1 binding to the IGF2 P3 promoter and IGF2 
expression is cell type-specific, and that the PLAG1 transcription factor acts as a 
transcriptional facilitator that partially overrides the insulation by the H19 ICR in 
some cell contexts. 
 
 
 
Figure 26. ChIP result showing PLAG1 binding at H19 ICR 
 44 
 
 
 
 
 
 
 
 
Over-expression of the IGF2 gene is a very frequent alteration in adrenocortical 
carcinoma (ACC) but not in adrenocortical adenoma (ACA). At the same time the 
functional evidences for a major tumor driving role of IGF2 are weak in ACC and in 
other tumors where IGF2 over-expression is frequent
135,136
. The IGF2 gene is situated 
in the imprinted IGF2/H19 locus from which additional molecules are generated that 
may each potentially contribute to ACC development.  These include miR-483-3p and 
miR-483-5p transcribed from IGF2, H19 and miR-675 transcribed from H19, and 
HOTS. The purpose of this study was to explore aberrations at H19/IGF2 locus in ACC 
and relate this to protein expression profiles determined by proteomics and reported 
elsewhere (Eriksson et al. in manuscript). A screening series of 5 normal adrenal 
cortices, 6 ACAs and 8 ACCs was first used. An extended series of 9 normal adrenal 
cortices, 43 samples of ACAs and 30 samples of ACCs were then used for verification 
of findings by qRT-PCR. 
 
Expression of IGF2, H19, HOTS and PLAG1 
Using qRT-PCR in the screening series we found that IGF2 was increased in ACCs 
compared to ACA and control samples. Elevated levels of H19 were observed in 
almost all ACAs, while all ACCs showed down regulation of H19. We also included 
HOTS and PLAG1 expression at the mRNA level in our study group.  All samples 
showed homogenous expression of HOTS and PLAG1 mRNA without clear 
discrepancy between the ACA and ACC. This result suggested that PLAG1 and HOTS 
are not important for the development of ACC. Hence, HOTS and PLAG1 were 
excluded from further investigation. 
 
Expression of miR-483-3P, miR-483-5P and miR-675. 
miRNA generated from the H19/IGF2  locus are miR-483-3P, miR-483-5P and miR-
675. miR-483-3P and miR-483-5P created from the IGF2 locus were up regulated in 
ACCs compared to ACAs and control, whereas miR-675 produced from the H19 locus 
4.4  
Paper IV 
Proteome profiles associated with alterations of 
the IGF2/H19   locus and malignancy in 
adrenocortical tumors. 
  
was down regulated in ACCs in relation to ACAs. Because of diverse expression 
between the two groups of tumors, we further analyzed these transcripts in an extended 
series of samples. miR-483-3P, miR-483-5P and IGF2 mRNAs were up-regulated in 
ACCs compared to ACAs and control, whereas H19 mRNAs and miR-675 showed 
down-regulation in the ACC group. This association between mRNAs and miRNAs 
investigated in the extended series disclosed a weak inverse correlation between IGF2 
and H19. Positive correlations were observed between IGF2 and miR-483-3P and miR-
483-5P, as well as between H19 and miR-675. 
 
Infrequent loss of imprinting in ACC 
To assess the allelic expression of the imprinted IGF2, an ApaI polymorphism in exon 
9 of the IGF2 gene was used in our screening of genomic DNA from the 8 ACCs and 6 
ACAs. We identified in total eight informative samples based on restriction fragment 
length polymorphism, RFLP, which we perceived after ApaI digestion, i.e. 
heterozygosity for the ApaI site. These eight informative samples were further analyzed 
for detection of loss of functional imprinting (LOI) of the silenced allele. Two samples 
of the eight showed LOI of IGF2, of which one showed complete LOI whereas the 
other was indicative of partial LOI. The cases with LOI were both in the ACCs group, 
and LOI did not correlate with expression of HOTS or PLAG1. The sample that showed 
complete LOI exhibited higher expression of IGF2 and the IGFII protein. 
 
Figure 27. Informative samples and samples with LOI. 
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Comparison of transcripts and protein expression profiles 
The proteomic analysis revealed a good correlation between IGF2 mRNA and IGFII 
protein levels.  ACCs which showed higher IGF2  mRNAs also showed increased 
protein expression. The ACAs displayed low IGF2 and also low IGFII. The 
relationship of IGF II protein with IGF2  mRNA demonstrated a positive correlation 
between ( r = 0.52; P = 0.055). 
Mass spectrometry data obtained for the screening series of eight ACCs and six ACAs 
was employed. We compared these proteomic data with our mRNAs and miRNAs. 
With good significance, six proteins were correlated to IGF2 mRNA and miR-483-3P, 
48 proteins correlated to IGF2 mRNA and miR-483-5P. 120 proteins overlapped for 
the IGF2 mRNA, miR-483-3P and miR-483-5P correlations. Only four proteins 
correlated with H19 and miR-67. Association of the proteomic data with IGF2 and H19 
expression revealed 222 proteins correlating with IGF2 and 71 proteins correlating to 
H19. We also identified proteins that inversely correlate with these three transcripts. By 
this we found seven proteins which inversely correlate to miR-483-3P expression 
among which two were predicted targets using three prediction programs from 
miRecords. Including 20 predicted targets, we found 101 proteins that correlated 
inversely with miR-483-5P. Eleven inversely correlated proteins to miR-67 were 
identified.  
 
IGF2 and H19 gene networks 
To assess the theoretical interactions and cellular networks of IGF2 and H19 
correlating proteins, we used the Ingenuity Pathway Analysis “omics” data (IPA 
version 14400082; Ingenuity® System, www.ingenuity.com). Top networks for IGF2 
were composed of 34 molecules which implicate RNA post-transcriptional 
modification, expression of gene and molecular transport. The H19 top network 
correlated proteins characterizes 18 molecules associated with lipid metabolism, 
molecular transport and small molecular biochemistry. 
In conclusion, IGF2/H19 locus deregulation implicates up-regulation of IGF2 at 
mRNA and protein levels, along with miR-483-3P and miR-483-5P produced from this 
locus, as well as down regulation of H19 with its miR-675. Overexpressed protein and 
miRNAs identified at the IGF2/H19 locus in ACCs in comparison to ACAs may be 
established as therapeutic marker and for follow-up of patients. 
  
5. CONCLUDING REMARKS 
 
The development of cancer is a highly complex process, in which genetic and 
epigenetic alterations may contribute alone or in combination. While the field of cancer 
genetics is since long well-established, cancer epigenetics is a relatively younger but 
expanding research area. This thesis is focused on epigenetic modifications in cancer 
from both a descriptive and potentially therapeutic perspective.  Epigenetics may be 
defined as heritable modifications of the chromatin that do not include changes in the 
DNA sequence or the proteins connected to DNA. The epigenetic modifications known 
today include DNA methylation, histone modification and RNA induced silencing. The 
findings in this thesis will help to better understand epigenetic aspects of altered 
methylation and histone modification in neural progenitor cells, for employment as 
therapy vector; the role of the transcription factor PLAG1 in regulation of the imprinted 
gene IGF2;  and alterations of the imprinted IGF2/H19 locus  in adrenocortical 
carcinoma. The results can be summarized as follows: 
 
1. We wanted to explore how neural progenitor cells (NPCs) could be used as 
vectors for carrying a suicide gene. The important gap junction 
communication between the vector cells and the target cancer cells was 
studied and attempts to stimulate it with epigenetic drugs were tested. Our 
result provides better understanding about the effect of HDACi on the gap 
junctional protein connexin 43 between NPCs and glioblastoma multiforme 
cells and we propose that HDACi treated NPCs may act as a potential 
vector for glioblastoma treatment. 
2.  In continuation of the first paper, it is important to understand how HDACi 
affect the differentiation potential of the attempted suicide gene vector cells, 
since differentiation is negatively correlated with cell migration and cancer 
cell tropism. We showed that HDACi prevented differentiation, possibly 
through involvement of DNMT3A. This emphasizes the usefulness of 
HDACi as an inducer of gap junction communication  and NPC migration. 
3. The importance of PLAG1 as a facilitator of IGF2 transcription was 
studied. We found that PLAG1 display cell type-specific binding efficiency 
to the IGF2 P3 promoter and that it appears to partially overcome the H19 
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insulator in a construct containing an imprinting control region. The 
transcription factor PLAG1 may therefore have a cell type-specific role on 
regulation of IGF2 P3 promoter activity. 
4. Abnormalities at the H19/IGF2 locus in adrenocortical carcinoma include 
over-expression of IGF2 and miR-483 under-expression of H19 and miR-
675. The alterations are associated with altered protein expression profiles 
including potential diagnostic markers.  
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